Results 151 to 160 of about 1,979,548 (395)
Across seven centers (2015–2023), we studied 1634 ATAAD patients undergoing TAR+FET and, after propensity matching (n = 699), compared elderly (≥ 60) versus non‐elderly (< 60) outcomes. Elderly patients had higher 30‐day mortality and complications (log‐rank p = 0.002), supporting individualized hybrid strategies, organ‐protective perioperative care ...
Jiajun Liang +11 more
wiley +1 more source
The Role of Extracellular Vesicles MicroRNAs in Sarcopenia: From Aging to Multi‐Morbidity
Exosomes transporting miRNAs play a crucial bidirectional regulatory role in the process of sarcopenia, both in natural aging and under various pathological conditions. ABSTRACT Sarcopenia, defined as progressive loss of skeletal muscle mass and function, occurs during aging and has also been recognized for its detrimental effects in various disease ...
Bingyu Huang, Zhao Peng, Lin Kang
wiley +1 more source
This single‐center retrospective study evaluated perioperative outcomes after hepatectomy in 749 patients, including 140 receiving ATT, using propensity score matching to compare ATT and non‐ATT cohorts. Under standardized perioperative management, ATT did not increase major bleeding, transfusion, or severe morbidity overall; however, within the ATT ...
Haruki Mori +9 more
wiley +1 more source
ACUTE MYOCARDIAL INFARCTION IN ISFAHAN, IRAN: HOSPITALIZATION AND 28TH DAY CASE-FATALITY RATE
BACKGROUND: This study aimed to investigate 28-day case fatality rate due to acute myocardial infarction (MI) in Isfahan using a standardized surveillance system.
Nizal Sarrafzadegan +4 more
doaj
ABSTRACT The rapid evolution of the Internet of Things (IoT) has significantly advanced the field of electrocardiogram (ECG) monitoring, enabling real‐time, remote, and patient‐centric cardiac care. This paper presents a comprehensive survey of AI assisted IoT‐based ECG monitoring systems, focusing on the integration of emerging technologies such as ...
Amrita Choudhury +2 more
wiley +1 more source
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo +38 more
wiley +1 more source

